WallStreetZenWallStreetZen

NASDAQ: ENTX
Entera Bio Ltd Stock

$2.52-0.46 (-15.44%)
Updated Apr 15, 2024
ENTX Price
$2.52
Fair Value Price
$0.37
Market Cap
$89.41M
52 Week Low
$0.52
52 Week High
$3.35
P/E
-8.13x
P/B
8.61x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.89M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$7M
Beta
0.52
Next Earnings
May 3, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ENTX Overview

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ENTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ENTX ($2.52) is overvalued by 587.74% relative to our estimate of its Fair Value price of $0.37 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ENTX ($2.52) is not significantly undervalued (587.74%) relative to our estimate of its Fair Value price of $0.37 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ENTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ENTX due diligence checks available for Premium users.

Be the first to know about important ENTX news, forecast changes, insider trades & much more!

ENTX News

Valuation

ENTX fair value

Fair Value of ENTX stock based on Discounted Cash Flow (DCF)
Price
$2.52
Fair Value
$0.37
Overvalued by
587.74%
ENTX ($2.52) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ENTX ($2.52) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ENTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ENTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-8.13x
Industry
14.94x
Market
41.94x

ENTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
8.61x
Industry
5.88x
ENTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ENTX's financial health

Profit margin

Revenue
$0.0
Net Income
-$2.0M
Profit Margin
0%
ENTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$11.8M
Liabilities
$1.4M
Debt to equity
0.13
ENTX's short-term assets ($11.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENTX's short-term assets ($11.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ENTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.6M
Investing
-$5.0k
Financing
$6.0M
ENTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ENTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ENTX$89.41M-15.44%-8.13x8.61x
DTIL$90.33M-7.51%-0.82x4.79x
DMAC$90.72M-1.65%-3.98x1.78x
CNTB$91.92M-2.91%-1.09x0.72x
CRIS$85.82M-4.71%-1.63x4.36x

Entera Bio Stock FAQ

What is Entera Bio's quote symbol?

(NASDAQ: ENTX) Entera Bio trades on the NASDAQ under the ticker symbol ENTX. Entera Bio stock quotes can also be displayed as NASDAQ: ENTX.

If you're new to stock investing, here's how to buy Entera Bio stock.

What is the 52 week high and low for Entera Bio (NASDAQ: ENTX)?

(NASDAQ: ENTX) Entera Bio's 52-week high was $3.35, and its 52-week low was $0.52. It is currently -24.78% from its 52-week high and 384.62% from its 52-week low.

How much is Entera Bio stock worth today?

(NASDAQ: ENTX) Entera Bio currently has 35,481,341 outstanding shares. With Entera Bio stock trading at $2.52 per share, the total value of Entera Bio stock (market capitalization) is $89.41M.

Entera Bio stock was originally listed at a price of $6.28 in Jun 28, 2018. If you had invested in Entera Bio stock at $6.28, your return over the last 5 years would have been -59.87%, for an annualized return of -16.69% (not including any dividends or dividend reinvestments).

How much is Entera Bio's stock price per share?

(NASDAQ: ENTX) Entera Bio stock price per share is $2.52 today (as of Apr 15, 2024).

What is Entera Bio's Market Cap?

(NASDAQ: ENTX) Entera Bio's market cap is $89.41M, as of Apr 16, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Entera Bio's market cap is calculated by multiplying ENTX's current stock price of $2.52 by ENTX's total outstanding shares of 35,481,341.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.